Enlivex Therapeutics (ENLV) Institutional Ownership $1.18 -0.03 (-2.48%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Enlivex Therapeutics (NASDAQ:ENLV)CurrentInstitutional OwnershipPercentage1.02%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$3.43MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$413.37K Get ENLV Insider Trade Alerts Want to know when executives and insiders are buying or selling Enlivex Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ENLV Institutional Buying and Selling by Quarter Enlivex Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2025Jane Street Group LLC80,759$78K0.0%+527.4%0.341% 5/15/2025Armistice Capital LLC1,781,931$1.73M0.0%-19.3%7.534% 2/17/2025Millennium Management LLC633,847$742K0.0%N/A2.961% 2/14/2025Two Sigma Securities LLC22,362$26K0.0%N/A0.104% 2/13/2025Renaissance Technologies LLC158,992$186K0.0%+112.6%0.743% 10/23/2024Sigma Investment Counselors Inc.30,000$50K0.0%N/A0.140% 8/15/2024Armistice Capital LLC1,700,571$2.42M0.0%N/A8.148% 8/12/2024XTX Topco Ltd24,820$35K0.0%N/A0.119% 5/1/2023Compagnie Lombard Odier SCmA65,000$225K0.0%+30.0%0.350% 2/9/2023Group One Trading L.P.13,499$53K0.0%+2,689.0%0.073% Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/11/2022ARK Investment Management LLC331,001$1.66M0.0%-23.8%1.802% 4/27/2022Compagnie Lombard Odier SCmA50,000$279K0.0%+16.3%0.273% 4/20/2022Belvedere Trading LLC14,473$101K0.0%-13.9%0.079% 4/19/2022ARK Investment Management LLC434,343$2.43M0.0%+24.3%2.372% 2/9/2022Compagnie Lombard Odier SCmA43,000$247K0.0%+22.9%0.235% 2/3/2022ACT Capital Management LLC25,000$156K0.1%-69.7%0.137% 1/28/2022ARK Investment Management LLC349,308$2.18M0.0%-23.7%1.908% 1/21/2022Golden Green Inc.19,967$125K0.1%-54.7%0.109% 11/12/2021Renaissance Technologies LLC87,989$869K0.0%-55.0%0.481% 10/28/2021Compagnie Lombard Odier SCmA35,000$353K0.0%+40.0%0.191% 10/8/2021Golden Green Inc.44,085$436K0.3%-4.2%0.241% 8/13/2021Renaissance Technologies LLC195,706$1.74M0.0%-32.6%1.242% 8/11/2021Banque Cantonale Vaudoise10,000$89K0.0%N/A0.063% 8/5/2021ARK Investment Management LLC514,807$4.58M0.0%+8.1%3.267% 7/17/2021Golden Green Inc.46,020$410K0.3%-34.1%0.292% 5/18/2021Jane Street Group LLC11,070$123K0.0%N/A0.070% 5/17/2021Edmond DE Rothschild Holding S.A.13,000$144K0.0%N/A0.082% 5/17/2021Goldman Sachs Group Inc.12,986$144K0.0%N/A0.082% 5/13/2021Renaissance Technologies LLC290,406$3.22M0.0%+4.0%1.843% 5/12/2021UBS Group AG10,872$120K0.0%-51.5%0.069% (Data available from 1/1/2016 forward) ENLV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENLV shares? During the previous two years, the following institutional investors and hedge funds held shares of Enlivex Therapeutics shares: Armistice Capital LLC ($1.73M), Millennium Management LLC ($742K), Renaissance Technologies LLC ($186K), Jane Street Group LLC ($78K), Sigma Investment Counselors Inc. ($50K), and XTX Topco Ltd ($35K), and Two Sigma Securities LLC ($26K).Learn more on Enlivex Therapeutics' institutional investors. What percentage of Enlivex Therapeutics' stock is owned by institutional investors? 1.02% of Enlivex Therapeutics' stock is owned by institutional investors. Learn more on ENLV's institutional investor holdings. Which institutional investors have been buying Enlivex Therapeutics' stock? The following institutional investors have purchased Enlivex Therapeutics' stock in the last 24 months: Armistice Capital LLC ($1.70M), Millennium Management LLC ($633.85K), Renaissance Technologies LLC ($84.20K), Jane Street Group LLC ($67.89K), Sigma Investment Counselors Inc. ($30K), XTX Topco Ltd ($24.82K), and Two Sigma Securities LLC ($22.36K). How much institutional buying is happening at Enlivex Therapeutics? Institutional investors have bought a total of 2,563,689 shares in the last 24 months. This purchase volume represents approximately $3.43M in transactions. Which of Enlivex Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Enlivex Therapeutics stock in the last 24 months: Armistice Capital LLC ($426.07K). How much institutional selling is happening at Enlivex Therapeutics? Institutional investors have sold a total of 426,069 shares in the last 24 months. This volume of shares sold represents approximately $413.37K in transactions. Related Companies KRRO Institutional Ownership VXRT Institutional Ownership GNLX Institutional Ownership TARA Institutional Ownership BHST Institutional Ownership THTX Institutional Ownership PROC Institutional Ownership CTNM Institutional Ownership ANIX Institutional Ownership MIST Institutional Ownership This page (NASDAQ:ENLV) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts